| Oct 10 |
Alpha Tau Treats First Patient with Recurrent Lung Cancer
|
| Sep 20 |
Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC
|
| Sep 17 |
Sidoti Events, LLC's Virtual September Small-Cap Conference
|
| Sep 3 |
DRTS: Company Seeks to Develop Significant Advance in Cancer Therapy with Alpha DaRT
|
| Aug 22 |
Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor...
|
| May 21 |
Alpha Tau to Present at the Jefferies Global Healthcare Conference
|
| May 20 |
Alpha Tau Medical GAAP EPS of -$0.11
|
| May 20 |
Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update
|
| May 6 |
Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow
|
